Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9.
Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, Brown CL, Chabot J, Gomes B, Garzone P, Rossi A, Strop P, Shelton D, Pons J, Rajpal A. Chaparro-Riggers J, et al. J Biol Chem. 2012 Mar 30;287(14):11090-7. doi: 10.1074/jbc.M111.319764. Epub 2012 Jan 31. J Biol Chem. 2012. PMID: 22294692 Free PMC article.
Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J, Wu S, Chin SM, Lee NA, Rossi A, Lin JC, Rajpal A, Pons J, Shelton DL. Liang H, et al. Among authors: shelton dl. J Pharmacol Exp Ther. 2012 Feb;340(2):228-36. doi: 10.1124/jpet.111.187419. Epub 2011 Oct 21. J Pharmacol Exp Ther. 2012. PMID: 22019884
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, Shelton DL, Forgues P, Billotte S, Pons J, Baum CM, Garzone PD. Gumbiner B, et al. Among authors: shelton dl. Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12309. Epub 2017 Nov 23. Cardiovasc Ther. 2018. PMID: 29078037 Free article. Clinical Trial.
Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy.
Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, Delaria K, Lui V, Poulsen K, Sutton J, Bolton G, Zhou D, Moine L, Dushin R, Tran TT, Liu SH, Rickert M, Foletti D, Shelton DL, Pons J, Rajpal A. Dorywalska M, et al. Among authors: shelton dl. PLoS One. 2015 Jul 10;10(7):e0132282. doi: 10.1371/journal.pone.0132282. eCollection 2015. PLoS One. 2015. PMID: 26161543 Free PMC article.
Modulation of P2X3 and P2X2/3 Receptors by Monoclonal Antibodies.
Shcherbatko A, Foletti D, Poulsen K, Strop P, Zhu G, Hasa-Moreno A, Melton Witt J, Loo C, Krimm S, Pios A, Yu J, Brown C, Lee JK, Stroud R, Rajpal A, Shelton D. Shcherbatko A, et al. J Biol Chem. 2016 Jun 3;291(23):12254-70. doi: 10.1074/jbc.M116.722330. Epub 2016 Apr 20. J Biol Chem. 2016. PMID: 27129281 Free PMC article.
Novel class of pain drugs based on antagonism of NGF.
Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM. Hefti FF, et al. Among authors: shelton dl. Trends Pharmacol Sci. 2006 Feb;27(2):85-91. doi: 10.1016/j.tips.2005.12.001. Epub 2005 Dec 27. Trends Pharmacol Sci. 2006. PMID: 16376998 Review.
80 results